UPB Stock Analysis: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$7.63
0.38 (5.24%)
▲
5d:
-7.63%
30d:
-18.05%
90d:
-2.18%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: UPB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: UPB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $7.63, which is considered oversold relative to its 30-day fair value range of $8.15 to $9.29.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $7.18, while resistance sits at $8.69. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: UPB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $42.43 (+456.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $7.18, while resistance sits at $8.69. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: UPB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $42.43 (+456.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.15 -
$9.29
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.2%)
- BULLISH: Trading 456.1% below Wall St target ($42.43)
- CAUTION: Recommendation downgraded due to -7.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$8.15 -
$9.29
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.22
(16.0%)
Support & Resistance Levels
Support Level
$7.19
Resistance Level
$8.69
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.53
Wall Street Target
$42.43
(+456.1%)
Revenue Growth (YoY)
82.7%
Share & Embed Analysis
Last updated: June 03, 2026 6:22 PM ET
Data refreshes hourly during market hours. Next update: 7:22 PM
Data refreshes hourly during market hours. Next update: 7:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Gray
SELL
852 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
